GemOx

GemOx or GEMOX is an acronym for one of the chemotherapy regimens, used in the treatment of relapsed or primary refractory non-Hodgkin's lymphoma and Hodgkin disease.

When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.

The [R]-GemOx regimen consists of:

  1. (R)ituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;
  2. (Gem)citabine - an antimetabolite;
  3. (Ox)aliplatin - a platinum-based antineoplastic agent with alkylating mechanism of action.[1][2]

Dosing regimen

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(Gem)citabine 1000 mg/m2 IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min Day 2
(Ox)aliplatin 100 mg/m2 IV infusion over 2hrs Day 2

References

  1. ↑ GEMOX-R regimen is a highly effective salvage regimen in patients with refractory / relapsing diffuse large-cell lymphoma: a phase II study
  2. ↑ Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
This article is issued from Wikipedia - version of the 10/14/2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.